Dimensional Fund Advisors
RNAC icon

Dimensional Fund Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Dimensional Fund Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-804
Closed -$15.7K – 3399
2024
Q1 		$15.7K Hold
804
– – ﹤0.01% 3374
2023
Q4 		$16.6K Hold
804
– – ﹤0.01% 3397
2023
Q3 		$25.6K Hold
804
– – ﹤0.01% 3428
2023
Q2 		$27K Sell
804
-991
-55% -$35.5K ﹤0.01% 3441
2023
Q1 		$74.9K Hold
1,795
– – ﹤0.01% 3347
2022
Q4 		$61 Sell
1,795
-2,860
-61% -$122K ﹤0.01% 3377
2022
Q3 		$229K Buy
+4,655
New +$256K ﹤0.01% 3213
2018
Q2 		– Sell
-585
Closed -$179K – 3376
2018
Q1 		$179K Sell
585
-139
-19% -$39.6K ﹤0.01% 3241
2017
Q4 		$213K Buy
+724
New +$316K ﹤0.01% 3215

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Dimensional Fund Advisors's RNAC Position: Q2 2024 in Review

Dimensional Fund Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 804 shares — an estimated $15.7K sold.

Dimensional Fund Advisors first reported a position in RNAC in Q4 2017 and held it in 9 quarters. The position peaked at $229K in Q3 2022. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • Dimensional Fund Advisors reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Dimensional Fund Advisors sold 804 Cartesian Therapeutics shares in Q2 2024, an estimated $15.7K.
  • Dimensional Fund Advisors first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 9 quarters.
  • Dimensional Fund Advisors's Cartesian Therapeutics position peaked at $229K in Q3 2022.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on Dimensional Fund Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.